Edward M. MD Kaye - Dec 3, 2024 Form 4/A - Amendment Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
CEO, Director
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Stock symbol
STOK
Transactions as of
Dec 3, 2024
Transactions value $
$0
Form type
4/A - Amendment
Date filed
12/10/2024, 06:59 PM
Date Of Original Report
Dec 5, 2024
Previous filing
Dec 3, 2024
Next filing
Dec 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $0 +26.3K +54.02% $0.00 74.8K Dec 3, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Performance Stock Units Award $0 +52.5K $0.00 52.5K Dec 3, 2024 Common Stock 52.5K Direct F1, F2, F3
transaction STOK Performance Stock Units Options Exercise $0 -26.3K -50% $0.00 26.3K Dec 3, 2024 Common Stock 26.3K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance stock unit represents a right to receive one share of the Issuer's common stock.
F2 This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.
F3 Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

Remarks:

This Form 4 is being amended to correct the number of performance-based restricted stock units awarded and vested on December 3, 2024 on Table II, and to correct the reporting person's total securities held on Table I accordingly.